Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells $22,696.70 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,686 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $8.45, for a total transaction of $22,696.70. Following the completion of the sale, the insider directly owned 420,047 shares of the company’s stock, valued at $3,549,397.15. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Relay Therapeutics Trading Down 0.6%

Shares of Relay Therapeutics stock opened at $7.66 on Friday. Relay Therapeutics, Inc. has a 12 month low of $1.77 and a 12 month high of $9.04. The stock’s fifty day simple moving average is $7.97 and its 200 day simple moving average is $5.99. The company has a market capitalization of $1.33 billion, a PE ratio of -4.38 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on RLAY shares. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a report on Monday, January 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Relay Therapeutics by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares during the period. Cresset Asset Management LLC increased its holdings in shares of Relay Therapeutics by 5.0% during the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after buying an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Relay Therapeutics by 8.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after purchasing an additional 2,079 shares in the last quarter. Prelude Capital Management LLC increased its stake in shares of Relay Therapeutics by 18.7% in the third quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock valued at $103,000 after buying an additional 3,100 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in Relay Therapeutics by 5.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 68,615 shares of the company’s stock valued at $237,000 after acquiring an additional 3,275 shares during the period. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.